Peanut Oral Immunotherapy Yields Higher Rates of Tolerance in High-Threshold Allergy
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 13, 2025 -- For children with high-threshold peanut allergy, peanut oral immunotherapy (P-OIT) using home-measured peanut butter ingestion yields higher and sustained rates of peanut tolerance, according to a study published online Feb. 10 in NEJM Evidence.
Scott H. Sicherer, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues randomly assigned participants aged 4 to 14 years reacting to a challenge of 443 to 5,043 mg of peanut protein to P-OIT using home-measured peanut butter or peanut avoidance (38 and 35 participants, respectively). The primary end point was the difference in the proportion of participants tolerating a two-dose-level increase or 9,043 mg of peanut protein. For ingestion participants tolerating 9,043 mg, sustained unresponsiveness (tolerance off treatment) was tested after 16 weeks of ingestion followed by eight weeks of abstinence.
The researchers found 100 and 21.0 percent success for ingestion versus avoidance, respectively, in the primary analysis. All 32 treated and three of 30 avoiders tolerated 9,043 mg; sustained unresponsiveness occurred in 68.4 versus 8.6 percent of P-OIT and avoidance participants tolerating 9,043 mg in the intention-to-treat analysis. There were no dosing reactions greater than grade 1 severity and no reports of serious adverse events.
"In children 4 to 14 years of age who were allergic to peanut but could tolerate more than 143 mg of protein at baseline, that high-dose, store-bought, home-measured P-OIT was effective in raising their threshold to serving size amounts of peanut with a durable response off treatment for the majority," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Skin Prick Automated Test Shows Equivalent Accuracy to Conventional Skin Prick Test
TUESDAY, July 15, 2025 -- Compared with the conventional skin prick test (SPT), the novel Skin Prick Automated Test (SPAT) shows equivalent accuracy to detect birch pollen or...
Cashew Identified as Increasingly Relevant Allergen Triggering Anaphylaxis in Children
WEDNESDAY, July 9, 2025 -- Cashew is an increasingly relevant allergen leading to anaphylaxis in children, according to a study published online June 13 in Allergy. Veronika...
Two-Hour Observation Probably Safe for Most Children With Anaphylaxis
THURSDAY, June 26, 2025 -- For most children who present to an emergency department with an acute allergic reaction requiring epinephrine, a two-hour observation period is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.